Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on May 12, 2010, at a price of £11.84 per share through the Company's Share Reward Plan. Each individual acquired 11 shares via a personal contribution (partnership element) and 11 shares via a company contribution (matching element). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £11.84 per Ordinary share on May 12, 2010.
- Confirm the total number of shares acquired by each listed director (22 shares per person: 11 personal + 11 matched).
- Review the specific terms of the Company's Share Reward Plan to understand the matching mechanism.
- Note that this filing does not reflect the company's broader financial health or operational results.